1.Effects of immediate extubation in the operating room on long-term outcomes in living donor liver transplantation: a retrospective cohort study
Jung-Pil YOON ; Ji-Uk YOON ; Hye-Jin KIM ; Seyeon PARK ; Yeong Min YOO ; Hong-Sik SHON ; Da Eun LEE ; Eun-Jung KIM ; Hee Young KIM
Anesthesia and Pain Medicine 2025;20(1):50-60
Background:
Living-donor liver transplantation (LDLT) is a viable alternative to deceased-donor liver transplantation. Enhanced recovery after surgery protocols that include early extubation offer short-term benefits; however, the effect of immediate extubation in the operating room (OR) on long-term outcomes in patients undergoing LDLT remains unknown. We hypothesized that immediate OR extubation is associated with improved long-term outcomes in patients undergoing LDLT.
Methods:
This retrospective cohort study included 205 patients who underwent LDLT. The patients were classified based on the extubation location as OREX (those extubated in the OR) or NOREX (those extubated in the intensive care unit [ICU]). The primary outcome was overall survival (OS), while secondary outcomes included ICU stay, hospital stay duration, and various postoperative outcomes.
Results:
Among the 205 patients, 98 (47.8%) underwent extubation in the OR after LDLT. Univariate analysis revealed that OR extubation did not significantly affect OS (hazard ratio [HR]: 0.50, 95% confidence interval [CI]: 0.24–1.05; P = 0.066). Furthermore, multivariate analysis revealed no statistically significant association between OR extubation and OS (HR: 0.79, 95% CI: 0.35–1.80; P = 0.580). However, OR extubation was significantly associated with a lower incidence of 30-day composite complications and shorter ICU and hospital stays. Multivariate analysis indicated that higher preoperative platelet counts, increased serum creatinine levels, and a longer surgery duration were associated with poorer OS.
Conclusions
Immediate OR extubation following LDLT surgery was associated with fewer 30-day composite complications and shorter ICU and hospital stays; however, it did not significantly improve OS compared with ICU extubation.
2.Capsosiphon fulvescens suppresses LPS-stimulated inflammatory responses by suppressing TLR4/NF-κB activation in RAW264.7 murine macrophages
Seon Yeong Ji ; EunJin Bang ; Hyun Hwangbo ; Min Yeong Kim ; Da Hye Kim ; Su Hyun Hong ; Shin- Hyung Park ; Chang-Young Kwon ; Gi-Young Kim ; You-Jin Jeon ; Suengmok Cho ; Yung Hyun Choi
Asian Pacific Journal of Tropical Biomedicine 2024;14(3):115-126
Objective: To evaluate the effects of Capsosiphon fulvescens (C. fulvescens) ethanolic extract on inflammation in lipopolysaccharide (LPS)-induced RAW296.7 macrophages. Methods: The protective effects of C. fulvescens ethanolic extract on LPS-induced inflammation in RAW264.7 macrophages were assessed using biochemical analysis, including enzyme-linked immunosorbent assay, quantitative reverse transcription-polymerase chain reaction, and Western blot analysis. To examine reactive oxygen species (ROS) production, flow cytometry analysis, and immunofluorescence staining were used. Furthermore, the modulatory effect of C. fulvescens ethanolic extract on NF-κB activation was investigated. Results: C. fulvescens ethanolic extract significantly attenuated LPS-induced levels of pro-inflammatory cytokines and notably reduced the secretion and mRNA levels of LPS-mediated matrix metalloproteinases. In addition, C. fulvescens ethanolic extract decreased ROS production and suppressed the TLR4/NF-κB signaling pathway. Conclusions: C. fulvescens ethanolic extract alleviates inflammation as well as oxidative stress by modulating the TLR4/NF-κB signaling in LPS-induced RAW264.7 macrophages. C. fulvescens can be used as a potential therapeutic agent to suppress inflammation and oxidative stress-associated diseases.
3.Asparagi radix alleviates testosterone-induced benign prostatic hyperplasia by inhibiting5α-reductase activity and androgenreceptor signaling pathway
Hyun HWANGBO ; Hee-Jae CHA ; Min Yeong KIM ; Seon Yeong JI ; Da Hye KIM ; Jeong Sook NOH ; Tae Hee KIM ; Heui-Soo KIM ; Sung-Kwon MOON ; Gi-Young KIM ; Yung Hyun CHOI
Nutrition Research and Practice 2024;18(6):793-805
BACKGROUND/OBJECTIVES:
Recently, herbal medicines have gained attention for the treatment of benign prostatic hyperplasia (BPH), a common disease in elderly men. In this study, we aimed to determine the effect of ethanol extract of Asparagi radix (EAR), which is traditionally used to treat various diseases, on BPH development using a testosteroneinduced BPH model.MATERIALS/METHODS: Testosterone propionate (TP)-treated Sprague–Dawley rats were used to establish a BPH model in vivo. EAR was orally administered along with TP, and finasteride was used as a positive control. All rats were sacrificed at the end of the experiment, and pathological changes in the prostate tissue and levels of key biomarkers associated with BPH pathogenesis were assessed.
RESULTS:
Oral administration of EAR significantly inhibited TP-induced BPH by reducing the prostate weight, lumen size, and epithelial thickness in a concentration-dependent manner. EAR also significantly abrogated the expression of 5α-reductase type 2 (SRD5A2), proliferating cell nuclear antigen, and prostate-specific antigen (PSA) induced by TP.Additionally, serum levels of testosterone, dihydrotestosterone, and PSA were elevated in the TP-induced group but decreased in the EAR-treated group. EAR also decreased the expression levels of the androgen receptor (AR) and its coactivators in TP-induced BPH model rats.
CONCLUSION
Our findings revealed that EAR protected against BPH by inhibiting 5α-reductase activity and AR signaling pathway, suggesting its potential for BPH treatment.
4.Asparagi radix alleviates testosterone-induced benign prostatic hyperplasia by inhibiting5α-reductase activity and androgenreceptor signaling pathway
Hyun HWANGBO ; Hee-Jae CHA ; Min Yeong KIM ; Seon Yeong JI ; Da Hye KIM ; Jeong Sook NOH ; Tae Hee KIM ; Heui-Soo KIM ; Sung-Kwon MOON ; Gi-Young KIM ; Yung Hyun CHOI
Nutrition Research and Practice 2024;18(6):793-805
BACKGROUND/OBJECTIVES:
Recently, herbal medicines have gained attention for the treatment of benign prostatic hyperplasia (BPH), a common disease in elderly men. In this study, we aimed to determine the effect of ethanol extract of Asparagi radix (EAR), which is traditionally used to treat various diseases, on BPH development using a testosteroneinduced BPH model.MATERIALS/METHODS: Testosterone propionate (TP)-treated Sprague–Dawley rats were used to establish a BPH model in vivo. EAR was orally administered along with TP, and finasteride was used as a positive control. All rats were sacrificed at the end of the experiment, and pathological changes in the prostate tissue and levels of key biomarkers associated with BPH pathogenesis were assessed.
RESULTS:
Oral administration of EAR significantly inhibited TP-induced BPH by reducing the prostate weight, lumen size, and epithelial thickness in a concentration-dependent manner. EAR also significantly abrogated the expression of 5α-reductase type 2 (SRD5A2), proliferating cell nuclear antigen, and prostate-specific antigen (PSA) induced by TP.Additionally, serum levels of testosterone, dihydrotestosterone, and PSA were elevated in the TP-induced group but decreased in the EAR-treated group. EAR also decreased the expression levels of the androgen receptor (AR) and its coactivators in TP-induced BPH model rats.
CONCLUSION
Our findings revealed that EAR protected against BPH by inhibiting 5α-reductase activity and AR signaling pathway, suggesting its potential for BPH treatment.
5.Asparagi radix alleviates testosterone-induced benign prostatic hyperplasia by inhibiting5α-reductase activity and androgenreceptor signaling pathway
Hyun HWANGBO ; Hee-Jae CHA ; Min Yeong KIM ; Seon Yeong JI ; Da Hye KIM ; Jeong Sook NOH ; Tae Hee KIM ; Heui-Soo KIM ; Sung-Kwon MOON ; Gi-Young KIM ; Yung Hyun CHOI
Nutrition Research and Practice 2024;18(6):793-805
BACKGROUND/OBJECTIVES:
Recently, herbal medicines have gained attention for the treatment of benign prostatic hyperplasia (BPH), a common disease in elderly men. In this study, we aimed to determine the effect of ethanol extract of Asparagi radix (EAR), which is traditionally used to treat various diseases, on BPH development using a testosteroneinduced BPH model.MATERIALS/METHODS: Testosterone propionate (TP)-treated Sprague–Dawley rats were used to establish a BPH model in vivo. EAR was orally administered along with TP, and finasteride was used as a positive control. All rats were sacrificed at the end of the experiment, and pathological changes in the prostate tissue and levels of key biomarkers associated with BPH pathogenesis were assessed.
RESULTS:
Oral administration of EAR significantly inhibited TP-induced BPH by reducing the prostate weight, lumen size, and epithelial thickness in a concentration-dependent manner. EAR also significantly abrogated the expression of 5α-reductase type 2 (SRD5A2), proliferating cell nuclear antigen, and prostate-specific antigen (PSA) induced by TP.Additionally, serum levels of testosterone, dihydrotestosterone, and PSA were elevated in the TP-induced group but decreased in the EAR-treated group. EAR also decreased the expression levels of the androgen receptor (AR) and its coactivators in TP-induced BPH model rats.
CONCLUSION
Our findings revealed that EAR protected against BPH by inhibiting 5α-reductase activity and AR signaling pathway, suggesting its potential for BPH treatment.
6.Asparagi radix alleviates testosterone-induced benign prostatic hyperplasia by inhibiting5α-reductase activity and androgenreceptor signaling pathway
Hyun HWANGBO ; Hee-Jae CHA ; Min Yeong KIM ; Seon Yeong JI ; Da Hye KIM ; Jeong Sook NOH ; Tae Hee KIM ; Heui-Soo KIM ; Sung-Kwon MOON ; Gi-Young KIM ; Yung Hyun CHOI
Nutrition Research and Practice 2024;18(6):793-805
BACKGROUND/OBJECTIVES:
Recently, herbal medicines have gained attention for the treatment of benign prostatic hyperplasia (BPH), a common disease in elderly men. In this study, we aimed to determine the effect of ethanol extract of Asparagi radix (EAR), which is traditionally used to treat various diseases, on BPH development using a testosteroneinduced BPH model.MATERIALS/METHODS: Testosterone propionate (TP)-treated Sprague–Dawley rats were used to establish a BPH model in vivo. EAR was orally administered along with TP, and finasteride was used as a positive control. All rats were sacrificed at the end of the experiment, and pathological changes in the prostate tissue and levels of key biomarkers associated with BPH pathogenesis were assessed.
RESULTS:
Oral administration of EAR significantly inhibited TP-induced BPH by reducing the prostate weight, lumen size, and epithelial thickness in a concentration-dependent manner. EAR also significantly abrogated the expression of 5α-reductase type 2 (SRD5A2), proliferating cell nuclear antigen, and prostate-specific antigen (PSA) induced by TP.Additionally, serum levels of testosterone, dihydrotestosterone, and PSA were elevated in the TP-induced group but decreased in the EAR-treated group. EAR also decreased the expression levels of the androgen receptor (AR) and its coactivators in TP-induced BPH model rats.
CONCLUSION
Our findings revealed that EAR protected against BPH by inhibiting 5α-reductase activity and AR signaling pathway, suggesting its potential for BPH treatment.
7.Asparagi radix alleviates testosterone-induced benign prostatic hyperplasia by inhibiting5α-reductase activity and androgenreceptor signaling pathway
Hyun HWANGBO ; Hee-Jae CHA ; Min Yeong KIM ; Seon Yeong JI ; Da Hye KIM ; Jeong Sook NOH ; Tae Hee KIM ; Heui-Soo KIM ; Sung-Kwon MOON ; Gi-Young KIM ; Yung Hyun CHOI
Nutrition Research and Practice 2024;18(6):793-805
BACKGROUND/OBJECTIVES:
Recently, herbal medicines have gained attention for the treatment of benign prostatic hyperplasia (BPH), a common disease in elderly men. In this study, we aimed to determine the effect of ethanol extract of Asparagi radix (EAR), which is traditionally used to treat various diseases, on BPH development using a testosteroneinduced BPH model.MATERIALS/METHODS: Testosterone propionate (TP)-treated Sprague–Dawley rats were used to establish a BPH model in vivo. EAR was orally administered along with TP, and finasteride was used as a positive control. All rats were sacrificed at the end of the experiment, and pathological changes in the prostate tissue and levels of key biomarkers associated with BPH pathogenesis were assessed.
RESULTS:
Oral administration of EAR significantly inhibited TP-induced BPH by reducing the prostate weight, lumen size, and epithelial thickness in a concentration-dependent manner. EAR also significantly abrogated the expression of 5α-reductase type 2 (SRD5A2), proliferating cell nuclear antigen, and prostate-specific antigen (PSA) induced by TP.Additionally, serum levels of testosterone, dihydrotestosterone, and PSA were elevated in the TP-induced group but decreased in the EAR-treated group. EAR also decreased the expression levels of the androgen receptor (AR) and its coactivators in TP-induced BPH model rats.
CONCLUSION
Our findings revealed that EAR protected against BPH by inhibiting 5α-reductase activity and AR signaling pathway, suggesting its potential for BPH treatment.
8.Dimethyl α-Ketoglutarate Promotes the Synthesis of Collagen and Inhibits Metalloproteinases in HaCaT Cells
Bo-Yeong YU ; Da-Hae EOM ; Hyun Woo KIM ; Yong-Joo JEONG ; Young-Sam KEUM
Biomolecules & Therapeutics 2024;32(2):240-248
We observed that treatment with dimethyl α-ketoglutarate (DMK) increased the amount of intracellular α-ketoglutarate significantly more than that of α-ketoglutarate in HaCaT cells. DMK also increased the level of intracellular 4-hydroxyproline and promoted the production of collagen in HaCaT cells. In addition, DMK decreased the production of collagenase and elastase and downregulated the expression of selected matrix metalloproteinases (MMPs), such as MMP-1, MMP-9, MMP-10, and MMP-12, via transcriptional inhibition. The inhibition of MMPs by DMK was mediated by the suppression of the IL-1 signaling cascade, leading to the attenuation of ERK1/2 phosphorylation and AP-1 transactivation. Our study results illustrate that DMK, an alkylated derivative of α-ketoglutarate, increased the level of 4-hydroxyproline, promoted the production of collagen, and inhibited the expression of selected MMPs by affecting the IL-1 cascade and AP-1 transactivation in HaCaT cells. The results suggest that DMK might be useful as an anti-wrinkle ingredient.
9.Smoking knowledge and smoking cessation intention according to the stage of change in smoking cessation behavior among smokers in their 20s
Hyoung-Joo KIM ; Jun-Yeong KWON ; Da-Eun KIM ; Hee-Jung LIM
Journal of Korean Academy of Oral Health 2024;48(3):117-123
Objectives:
The study aim was to analyze smoking knowledge and smoking cessation intentions according to the stage of change in smoking cessation behavior among smokers in their 20s. This program was implemented to prepare smoking cessation educational content in order to increase the success rate of smoking cessation.
Methods:
The analysis included 99 smokers in their 20s who lived in Seoul and Gyeonggi; the study period was February 14-16, 2024. After explaining the study purpose and obtaining consent for participation in the study, an online Google Forms survey was conducted.
Results:
Smoking cessation intention and smoking knowledge according to the smoking cessa-tion behavior change stage were significantly different depending on the presence of smokers and whether they attempted smoking cessation in the pre-contemplation period (P<0.05). In addition, the intention to quit smoking significantly increased in the pre-contemplation, contemplation, and preparation periods in the smoking cessation behavior change stage (P<0.001).
Conclusions
By operating a smoking cessation intervention program for smokers in their 20s, pro-viding correct smoking knowledge and finding ways to increase smoking cessation intention, smok-ers’ behavior can change and they can form a quitting habit. Therefore, we can expect that even middle-aged or older people can quit smoking.
10.Risk factors for severe postpartum hemorrhage requiring blood transfusion after cesarean delivery for twin pregnancy: a nationwide cohort study
Gi Hyeon SEO ; Jong Yeop KIM ; Da yeong LEE ; Changjin LEE ; Jiyoung LEE
Anesthesia and Pain Medicine 2023;18(4):367-375
Postpartum hemorrhage (PPH) is a leading cause of maternal morbidity and mortality. Twin pregnancy and cesarean delivery are well-known risk factors for PPH. However, few studies have investigated PPH risk factors in mothers who have undergone cesarean delivery for twin pregnancies. Therefore, this study investigated the risk factors associated with severe PPH after cesarean delivery for twin pregnancies. Methods: We searched and reviewed the Korean Health Insurance Review and Assessment Service’s claims data from July 2008 to June 2021 using the code corresponding to cesarean delivery for twin pregnancy. Severe PPH was defined as hemorrhage requiring red blood cell (RBC) transfusion during the peripartum period. The risk factors associated with severe PPH were identified among the procedure and diagnosis code variables and analyzed using univariate and multivariate logistic regressions. Results: We analyzed 31,074 cesarean deliveries for twin pregnancies, and 4,892 patients who underwent cesarean deliveries for twin pregnancies and received RBC transfusions for severe PPH were included. According to the multivariate analysis, placental disorders (odds ratio, 4.50; 95% confidence interval, 4.09– 4.95; P < 0.001), general anesthesia (2.33, 2.18–2.49; P < 0.001), preeclampsia (2.20, 1.99–2.43; P < 0.001), hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome (2.12, 1.22–3.68; P = 0.008), induction failure (1.37, 1.07–1.76; P = 0.014), and hypertension (1.31, 1.18–1.44; P < 0.001) predicted severe PPH. Conclusions: Placental disorders, hypertensive disorders such as preeclampsia and HELLP syndrome, and induction failure increased the risk of severe PPH after cesarean delivery for twin pregnancy


Result Analysis
Print
Save
E-mail